P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis

Catherine Scholz(Kura Oncology (United States)), Lisa Von Moltke, Tim Leach, Michael Patella(Millennium Engineering and Integration (United States)), Serap Sankoh(Millennium Engineering and Integration (United States)), Diane R. Mould(Phoenixville Hospital), A. Parikh(Takeda (United States)), T. Wyant, Irving H. Fox(Takeda (United States))
Journal of Crohn s and Colitis
January 31, 2009
10.1016/s1873-9946(09)60191-4
Cited by 4

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
The safety of vedolizumab for ulcerative colitis and Crohn's disease
|Gut|2016|810
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694